FORMULATION AND EVALUATION OF CREAMS CONTAINING CELECOXIB INCLUSIONS FOR TREATING PSORIATIC ARTHRITIS
Objective: The main objective of the present work was to prepare and evaluate creams of celecoxib inclusions which are nonsteroidal anti-inflammatory drug to treat psoriatic arthritis.
Methods: Celecoxib inclusions were prepared using β-cyclodextrin to increase the solubility. These inclusions were incorporated in creams. Cocoa butter, triethanolamine, stearic acid, methylparaben, gum acacia, and coconut oil were used in cream preparation. Fourier transform infrared and differential scanning calorimetry studies were carried out for pure celecoxib and inclusions. Viscosity, pH, homogeneity, and type of emulsion under dye test were evaluation parameters done for creams.
Results: All the results obtained were within the limits and confirmed increased solubility of celecoxib inclusions.
Conclusion: From the results obtained, increase in solubility of celecoxib drug was confirmed by forming inclusions using β-CD as polymer.
2. Gladman DD, Antonic, Mease P, Clegg DO, Nash P. Psoriatic arthritis: Epidemiology, clinical features, course, outcome. Ann Rheum Dis 2005;64:ii14-7.
3. Carol MP. Pathophysiology: Concepts of Altered Health States. 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004. p. 1428-9.
4. Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology 2016;151:110-9.
5. Damini N, Aniruddha M, Bina KM, Sugato B. Metabolic syndrome associated complications. Int J Pharm Pharm Sci 2015;7:22-5.
6. Camilla F. Genetic Studies of Psoriasis and Psoriatic Arthritis. Department of Medical and Clinical Genetics, Institute of Biomedicine. Gothenburg, Sweden: The Sahlgrenska Academy at Goteborg University Sweden; 2007.
7. DoQuyen H, Arthur K. Psoriatic arthritis: Current therapy and future approaches. Rheumatology 2015;54:20-8.
8. Eun JK, Arthur K. Psoriatic arthritis: Latest treatments and their place in therapy. Ther Adv Chronic Dis 2015;l6:194-203.
9. Jayashree V, Prakash R. Protective effect of COX inhibitors on lipopolysaccharide induced sickness behaviour or neuroinflammation and oxidative stress on male wistar rats. Int J Pharm Pharm Sci 2015;7:240-5.
10. Baskar R, Joseph RS, Rajesh M, Subramanian I, Palanichamy S, Thangathirupathi A. Formulation and evaluation of celecoxib loaded nanosized emulsion as transdermal drug delivery vehicle. Int J Pharm Sci Res 2010;1:41-9.
11. Goyal A, Kumar S, Nagpal M, Singh I, Arora S. Potential of novel drug delivery systems for herbal drugs. Ind J Pharm Res Educ 2011;45:225-35.
12. Martini A, Torricelli C, Muggetti L, Ponti RD. Use of dehydrated beta-cyclodextrin as pharmaceutical excipient. Drug Dev Ind Pharm 2008;20:2381-93.
13. Benjamas C, Jaruporn R. Inclusion complex formation of cyclodextrin with its guest and their applications. Biol Eng Med 2016;2:1-6.
14. Asmita S, Prerana V, Sudha. Design, development and characterization of liposomal neem gel. Int J Pharm Sci Res 2014;5:140-8.
15. Mahendra SK, Nityanand PV. Wrightia tinctoria R. Br. a review on its ethnobotany, pharmacognosy and pharmacological profile. J Coast Life Med 2014;2:826-40.
16. Shikha A, Nidhi S, Narendra. KJ, Agarwal GP. Solubility Enhancement of Poorly Water Soluble Celecoxib for Parenteral Formulations . Int. J. Pharm. Sci. Res 2012;3(7): 2325-36.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.